Payment overview · 2025
General Payments
$516.47
24 reported records · 10 companies
Healthcare provider profile · identity verified
Roussel Clement, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GROVES, TX · NPI 1710977913
Verified facts
What the public records show
CMS Open Payments records show Roussel Clement, MD received $516.47 in general payments during 2025 across 24 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.86 | 33.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.22 | 17.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.02 | 14.1% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $44.49 | 8.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.41 | 6.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.50 | 5.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.34 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.34 | 4.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.29 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.00 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.47 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.86 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $92.22 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.22 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.24 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.24 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $44.49 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 310 | 100 |
| Metformin Hcl | Metformin Hcl | 282 | 77 |
| Gabapentin | Gabapentin | 244 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 70 |
| Losartan Potassium | Losartan Potassium | 222 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 58 |
| Tramadol Hcl | Tramadol Hcl | 194 | 53 |
| Clonazepam | Clonazepam | 189 | 40 |
| Alprazolam | Alprazolam | 165 | 26 |
| Omeprazole | Omeprazole | 159 | 44 |
| Furosemide | Furosemide | 158 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 44 |
| Montelukast Sodium | Montelukast Sodium | 139 | 37 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 120 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 28 |
| Glipizide | Glipizide | 112 | 31 |
| Lisinopril | Lisinopril | 112 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 29 |
| Famotidine | Famotidine | 82 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 78 | 13 |
| Celecoxib | Celecoxib | 77 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Sertraline Hcl | Sertraline Hcl | 76 | 18 |
| Simvastatin | Simvastatin | 72 | 18 |
| Januvia | Sitagliptin Phosphate | 68 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 16 |
| Dexamethasone | Dexamethasone | 62 | 53 |
| Temazepam | Temazepam | 60 | 14 |
| Farxiga | Dapagliflozin Propanediol | 59 | 11 |
| Trazodone Hcl | Trazodone Hcl | 59 | 15 |
| Allopurinol | Allopurinol | 57 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 17 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 12 |
| Eliquis | Apixaban | 53 | 22 |
| Carvedilol | Carvedilol | 52 | 19 |
| Azithromycin | Azithromycin | 51 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 19 |
| Glipizide Er | Glipizide | 48 | 18 |
| Mirtazapine | Mirtazapine | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 15 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 12 |
| Bumetanide | Bumetanide | 45 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 42 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 14 |
| Nystatin | Nystatin | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Meloxicam | Meloxicam | 35 | 13 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 22 |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 22 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Baclofen | Baclofen | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | 12 |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fluorouracil | Fluorouracil | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.47 · 24 records | Bayer Healthcare Pharmaceuticals Inc. | COLLAGENASE SANTYL, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SUBLOCADE, UBRELVY, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error